CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Post-LOE

calcipotriene, betamethasone dipropionate

Design Pharmaceuticals

ANDATOPICALOINTMENT

Approved

Dec 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE (calcipotriene, betamethasone dipropionate) by Design Pharmaceuticals is 3 analogue and betamethasone dipropionate as a synthetic corticosteroid. Approved for psoriasis. First approved in 2014.

Drug data last refreshed Yesterday

Mechanism of Action

3 analogue and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.

Pharmacologic Class:

Vitamin D Analog

Indications (1)

psoriasis

Company

Worked on CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.